Rugged dsRNA Structure Enhances TLR3 Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ampligen® poly(I):poly(C12U) exhibits lower than expected biological activity due to its branching structure, which affects its therapeutic efficacy as a selective agonist for Toll-like receptor 3 (TLR3).
Innovation Solution
Development of a new form of double-stranded ribonucleic acid (dsRNA) with a 'rugged' molecular structure, resistant to molecular unfolding and denaturation, which is enriched to become the dominant structure in the Ampligen® mixture, enhancing its biological activity as a selective agonist for TLR3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If poly(I):poly(C12U) is used as a therapeutic agent, then it can activate TLR3 and induce interferon synthesis, but its biological activity is lower than expected due to branching structure and susceptibility to hydrolysis
Solution Approach 1:
The patent changes the structural parameters of dsRNA by controlling molecular weight (50-500 base pairs), optimizing the C:U ratio (30:1 to 1:1), and controlling helical turn number (4-50 turns). These parameter changes create a 'rugged' structure that resists unfolding and branching, thereby improving both biological activity and structural stability simultaneously
Solution Approach 2:
The patent creates a composite dsRNA structure with specific composition (poly(I):poly(CxUy)) where the ratio of cytidine to uridine is optimized to prevent branching while maintaining TLR3 activation capability. This composite structure combines the benefits of stability from poly(I) with the controlled degradation and reduced toxicity from poly(CxUy)
2Object-affected harmful factors
If poly(I):poly(C) is modified by introducing uridylate to reduce toxicity, then adverse effects are lessened, but the ability to induce interferon synthesis may be compromised
Solution Approach 1:
The patent optimizes the C:U ratio parameter within specific ranges (30:1 to 1:1) to achieve the right balance between reduced toxicity and maintained interferon induction capability. This parameter optimization ensures that uridylate introduction reduces toxicity while preserving therapeutic efficacy
Solution Approach 2:
The patent uses circular dichroism analysis to monitor and control the secondary structure of dsRNA, ensuring that the modified structure maintains the double-helical conformation necessary for TLR3 binding and interferon induction while exhibiting reduced toxicity
3Reliability
If dsRNA is used as a therapeutic agent, then it can activate immune response, but it is susceptible to hydrolysis and degradation in physiological environments
Solution Approach 1:
The patent controls the molecular weight parameter (50-500 base pairs) and helical structure parameters to create a rugged dsRNA structure that is resistant to hydrolysis and nuclease degradation. This extends the half-life of dsRNA in physiological environments while maintaining immune activation efficacy
Solution Approach 2:
The patent accepts that dsRNA will eventually degrade but optimizes its structure to maximize the functional half-life. The controlled degradation through optimized C:U ratio and molecular weight ensures that the dsRNA maintains activity long enough to achieve therapeutic effect before natural degradation occurs
Data Source
AI summary
A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C30,U) has a reduced tendency to form branched dsRNA which results in increased bioactivity due to an increased ability to bind TLR3 receptor. Pharmaceutical formulations containing the new nucleic acid as active ingredients and methods of treatment are also provided. The invention also provides a description of the physicochemical properties of this novel form of Rugged dsRNA and a method for its preparation in substantially pure form. DsRNAs acting thru TLR3 receptor activation are potent antiviral compounds as well as anticancer agents; also through secondary immunomodulation they can enhance the bioactivity of vaccines and also treat autoimmune disorders.